Literature DB >> 25698398

Necroptosis-inducing rhenium(V) oxo complexes.

Kogularamanan Suntharalingam1, Samuel G Awuah, Peter M Bruno, Timothy C Johnstone, Fang Wang, Wei Lin, Yao-Rong Zheng, Julia E Page, Michael T Hemann, Stephen J Lippard.   

Abstract

Rhenium(V) oxo complexes of general formula [ReO(OMe)(N^N)Cl2], where N^N = 4,7-diphenyl-1,10-phenanthroline, 1, or 3,4,7,8-tetramethyl-1,10-phenanthroline, 2, effectively kill cancer cells by triggering necroptosis, a non-apoptotic form of cell death. Both complexes evoke necrosome (RIP1-RIP3)-dependent intracellular reactive oxygen species (ROS) production and propidium iodide uptake. The complexes also induce mitochondrial membrane potential depletion, a possible downstream effect of ROS production. Apparently, 1 and 2 are the first rhenium complexes to evoke cellular events consistent with programmed necrosis in cancer cells. Furthermore, 1 and 2 display low acute toxicity in C57BL/6 mice and reasonable stability in fresh human blood.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25698398      PMCID： PMC4702498          DOI： 10.1021/ja511978y

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN： 0002-7863            Impact factor:   15.419


  64 in total

1.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Rhenium(IV) compounds inducing apoptosis in cancer cells.

Authors:  José Martínez-Lillo; Teresa F Mastropietro; Rosamaria Lappano; Antonio Madeo; Marta E Alberto; Nino Russo; Marcello Maggiolini; Giovanni De Munno
Journal:  Chem Commun (Camb)       Date:  2011-03-29       Impact factor: 6.222

3.  Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis.

Authors:  Vladislav Temkin; Qiquan Huang; Hongtao Liu; Hiroyuki Osada; Richard M Pope
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

4.  Requirement of FADD, NEMO, and BAX/BAK for aberrant mitochondrial function in tumor necrosis factor alpha-induced necrosis.

Authors:  Krishna M Irrinki; Karthik Mallilankaraman; Roshan J Thapa; Harish C Chandramoorthy; Frank J Smith; Neelakshi R Jog; Rajesh Kumar Gandhirajan; Steven G Kelsen; Steven R Houser; Michael J May; Siddharth Balachandran; Muniswamy Madesh
Journal:  Mol Cell Biol       Date:  2011-07-11       Impact factor: 4.272

5.  Cytotoxicity of rhenium(I) alkoxo and hydroxo carbonyl complexes in murine and human tumor cells.

Authors:  Y K Yan; S E Cho; K A Shaffer; J E Rowell; B J Barnes; I H Hall
Journal:  Pharmazie       Date:  2000-04       Impact factor: 1.267

Review 6.  Molecular mechanisms of necroptosis: an ordered cellular explosion.

Authors:  Peter Vandenabeele; Lorenzo Galluzzi; Tom Vanden Berghe; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2010-09-08       Impact factor: 94.444

7.  Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives.

Authors:  Kosuke Dodo; Miho Katoh; Tadashi Shimizu; Masahiro Takahashi; Mikiko Sodeoka
Journal:  Bioorg Med Chem Lett       Date:  2005-06-15       Impact factor: 2.823

Review 8.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

9.  Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation.

Authors:  Young Sik Cho; Sreerupa Challa; David Moquin; Ryan Genga; Tathagat Dutta Ray; Melissa Guildford; Francis Ka-Ming Chan
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

10.  Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.

Authors:  Yao-Rong Zheng; Kogularamanan Suntharalingam; Timothy C Johnstone; Hyunsuk Yoo; Wei Lin; Jamar G Brooks; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2014-06-06       Impact factor: 15.419
View more
  16 in total

1.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Authors:  Peter M Bruno; Yunpeng Liu; Ga Young Park; Junko Murai; Catherine E Koch; Timothy J Eisen; Justin R Pritchard; Yves Pommier; Stephen J Lippard; Michael T Hemann
Journal:  Nat Med       Date:  2017-02-27       Impact factor: 53.440

2.  Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage.

Authors:  Yao-Rong Zheng; Kogularamanan Suntharalingam; Peter M Bruno; Wei Lin; Weixue Wang; Michael T Hemann; Stephen J Lippard
Journal:  Inorganica Chim Acta       Date:  2016-03-25       Impact factor: 2.545

3.  Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity.

Authors:  Samuel G Awuah; Imogen A Riddell; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

4.  Unprecedented anticancer activities of organorhenium sulfonato and carboxylato complexes against hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cells.

Authors:  Paul T Wilder; David J Weber; Angela Winstead; Sabreea Parnell; Tiara V Hinton; Monet Stevenson; Dipak Giri; Samira Azemati; Pola Olczak; Brent V Powell; Tijesunimi Odebode; Solomon Tadesse; Yongchao Zhang; Saroj K Pramanik; James M Wachira; Sujan Ghimire; Pumtiwitt McCarthy; Alexis Barfield; Hirendra N Banerjee; Chao Chen; James A Golen; Arnold L Rheingold; Jeanette A Krause; Douglas M Ho; Peter Y Zavalij; Roosevelt Shaw; Santosh K Mandal
Journal:  Mol Cell Biochem       Date:  2017-09-14       Impact factor: 3.396

5.  In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes.

Authors:  Kevin M Knopf; Brendan L Murphy; Samantha N MacMillan; Jeremy M Baskin; Martin P Barr; Eszter Boros; Justin J Wilson
Journal:  J Am Chem Soc       Date:  2017-09-26       Impact factor: 15.419

6.  In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex.

Authors:  Chilaluck C Konkankit; A Paden King; Kevin M Knopf; Teresa L Southard; Justin J Wilson
Journal:  ACS Med Chem Lett       Date:  2019-04-23       Impact factor: 4.345

7.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

8.  Nucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin.

Authors:  Imogen A Riddell; Timothy C Johnstone; Ga Young Park; Stephen J Lippard
Journal:  Chemistry       Date:  2016-04-25       Impact factor: 5.236

Review 9.  Cancer therapy in the necroptosis era.

Authors:  Z Su; Z Yang; L Xie; J P DeWitt; Y Chen
Journal:  Cell Death Differ       Date:  2016-02-26       Impact factor: 15.828

10.  Anticancer gold(iii)-bisphosphine complex alters the mitochondrial electron transport chain to induce in vivo tumor inhibition.

Authors:  Jong Hyun Kim; Samuel Ofori; Sean Parkin; Hemendra Vekaria; Patrick G Sullivan; Samuel G Awuah
Journal:  Chem Sci       Date:  2021-04-29       Impact factor: 9.825
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.